drugset / Trial / NCT04603508
Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/10 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
Timeline
- Start
- 2023-03
- Primary completion
- 2025-04
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BERLIM 25/10 association | Unknown | — | Oral |
| Comparator | Empagliflozin | Small molecule | 25 mg | Oral |
| Comparator | Rosuvastatin | Small molecule | 10 mg | Oral |